Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. (Q53535574)
Jump to navigation
Jump to search
scientific article published on 16 April 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. |
scientific article published on 16 April 2015 |
Statements
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08 (English)
Khalil Zaman
Ralph Winterhalder
Christoph Mamot
Ursula Hasler-Strub
Christoph Rochlitz
Catherine Berset
Hans Wiliders
Lucien Perey
Christine Biaggi Rudolf
Hanne Hawle
Stephanie Rondeau